CEACAM5-BINDING ANTIBODIES
VN129069APending Publication Date: 2026-09-15F HOFFMANN LA ROCHE & CO AG
0 Cites 0 Cited by
Patent Information
- Application Number
- VN1202604969
- Authority / Receiving Office
- VN · VN
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-12-20
- Filing Date
- 2024-12-18
- Publication Date
- 2026-09-15
AI Technical Summary
Technical Problem
Existing anti-CEACAM5 antibodies, such as the humanized variant 1 (T84.66-LCHA), suffer from poor expression properties in common mammalian expression systems, limiting their therapeutic potential.
Method used
Development of novel antibodies that bind to CEACAM5, with specific heavy and light chain variable regions, designed to improve expression properties while maintaining high affinity and specificity.
Benefits of technology
The new antibodies demonstrate enhanced expression yields and maintain high binding affinity and specificity to CEACAM5, making them more suitable for therapeutic applications.
✦ Generated by Eureka AI based on patent content.
Abstract
The invention relates generally to an antibody that binds to CEACAM5. In addition, the invention relates to the polynucleotide encoding this antibody, and to the vector and host cell containing this polynucleotide. The invention also relates to a method for producing the antibody, and describes a method for using it in the treatment of disease.
Need to check novelty before this filing date? Find Prior Art